Steroid therapy in acute cerebral infarction

Area of Science:

• Neurology
• Clinical Medicine
• Pharmacology

Background:

• Acute cerebral infarction, or stroke, is a leading cause of death and disability.
• Corticosteroids like dexamethasone are sometimes considered for neuroprotection in stroke, but their efficacy remains debated.

Purpose of the Study:

• To evaluate the efficacy and safety of dexamethasone in patients with acute cerebral infarction.
• To compare outcomes between patients receiving dexamethasone and placebo within 24 hours of stroke onset.

Main Methods:

• A double-blind, placebo-controlled study involving 53 patients with acute cerebral infarction.
• Patients received either dexamethasone or placebo within 24 hours of stroke onset.
• Outcomes were assessed at 28 days post-stroke.

Main Results:

• Patients treated with dexamethasone showed slightly worse outcomes compared to the placebo group at 28 days.
• Mortality due to cerebral edema was higher in the dexamethasone group (3/7 deaths) than in the placebo group (2/5 deaths).
• Infectious complications, gastrointestinal hemorrhage, and diabetes exacerbations were more frequent in the dexamethasone group.

Conclusions:

• Dexamethasone treatment did not improve outcomes in acute cerebral infarction and was associated with increased adverse events.
• The use of dexamethasone in acute stroke patients requires careful consideration due to potential risks.